Download Flash Player ►
Epistem
www.epistem.co.uk/Profil
Epistem ist ein biotechnisches Unternehmen, dass sich auf Epithel -
Stammzellen im Bereich Onkologie und gastrointestinale Krankheiten und dermatologische Anwendungen konzentriert. Epistem ist bekannt als ein Spezialist in epithel-gewebe und Stammzellen Auswertungen. Unser Erbe ist basierend auf unsere erfahrene Wissenschaft und Innovation im Bereich der Epithelgewebe und Erwachsenen epithelialen Stammzellbiologie.
Aktienkurs
Vorstellungen
Keine Unterlagen verfügbar.
Verbundene Recherche
Keine Unterlagen verfügbar.
Unternehmensstrategie und – daten:
Epistem is a biotechnology company applying its expertise in epithelial stem cells in the areas of oncology and gastrointestinal diseases as well as dermatological applications.
Epistem has become recognised as a specialist in epithelial tissue and stem cell analyses. Our heritage is based on our expert science and know-how in the field of epithelial tissue and adult epithelial stem cell biology.
Epistem does not conduct research into embryonic stem cells or stem cell transplantation.
Founded in 2000, the Company originally formed part of the Paterson Institute for Cancer Research, UK. The founders and management are international experts in epithelial tissue, tumours and stem cell control and lead a team of experienced scientific staff, with specialist skills in the field.
Located in purpose-built office and laboratory facilities adjacent to The University of Manchester, UK, Epistem maintains close links with drug development companies, clinicians and academics in the field, ensuring that the Company remains at the forefront of stem cell science and technology development.
Scientific Overview
Epistem's scientific foundation is based on co-founder Professor Chris Potten's groundbreaking stem cell research over three decades at the Paterson Institute for Cancer Research at the Christie Hospital in Manchester, UK. Professor Potten identified and characterised the location and behaviour of stem cells in the intestine, skin, hair follicle and breast.
The epithelium provides a barrier between the body and its environment. Due to its dynamic epithelial change and rapid cell proliferative state, the lining of the small intestine provides a unique environment in which to understand epithelial changes, cell regulation and mechanisms of action. The lining of the intestine consists of a single layer of cells that secretes and absorbs substances during digestion. It undergoes continuous renewal; the finger-like villi in the small intestine in humans completely regenerates each week.
Stem cells are the source of life long tissue renewal (for an introduction to stem cells visit
http://www.eurostemcell.org/films#story
). These cells have the unique capability to either make more of themselves or to differentiate and give rise to all types of cells in a tissue. Small changes in stem cell activity result in large changes in the output of functional cells. The regulators that control epithelial stem cells in the body remain unknown. Epistem is in the unique position to discover these regulators and develop new therapeutics that modulate the body's own stem cells to protect and repair epithelial tissues in patients.
The Epistem team have developed powerful models to elucidate the mechanism of action of cells and to characterise the escalator-like process of cell production required to maintain the integrity of epithelial tissues. These models remain unmatched, in the field of stem cell biology, for studying the behaviour of adult (non-embryonic) stem cells.
Epistem's discovery platform integrates its unparalleled knowledge of stem cells and models alongside proprietary high-resolution gene expression profiling technology.
Aktuelle Tätigkeiten:
Epistem is a specialist contract research organisation providing reliable, innovative research models, preclinical efficacy testing and clinical sample analysis to the pharmaceutical, biotechnology and personal care industries.
Epistem has a world-renowned expertise in adult epithelial stem cell biology. Epithelial tissue is implicated in a wide variety of diseases and the company provides a comprehensive range of preclinical models in four key therapeutic areas.
Oncology
Epistem's preclinical oncology platform is an integrated offering, combining a comprehensive range of assays with a high level of oncology expertise. Epistem has a track record of delivering high quality preclinical data to our pharmaceutical clients, many of which have progressed towards the clinical phases.
Epistem's preclinical oncology platform includes:
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD)
describes two separate disorders: Crohn's disease and ulcerative colitis (UC). Both are characterised by chronic inflammation of the gastrointestinal mucosa, resulting in ulceration, mucosal bleeding and diarrhoea. Defects in both the adaptive and innate immune response to antigens of bacterial origin are thought to promote these diseases.
Epistem's IBD service platform comprises a comprehensive range incorporating:
Target validation :
Access to human diseased tissue (Crohn's and UC)
Immunohistochemistry and Ariol image analysis
Gene expression profiling
(qRT-PCR)
In vitro compound testing:
In vitro model of T-cell and B-cell help
Assessment of interleukin production, by ELISA
Preclinical inflammatory bowel disease models :
Acute models (DSS and TNBS)
Chronic models (
CD4+CD62L+ adoptive T-cell transfer
and
IL-10 knockout
)
Oncology Supportive Care (Mucositis)
Mucositis
is a dose-limiting side-effect of many cancer therapies. Interruption of gastrointestinal cell production by a cytotoxic agent can result in a breach of the mucosal barrier. If sufficient
epithelial
stem cells are killed, severe, debilitating ulceration and diarrhoea can arise. Commercially available models for oral and intestinal mucositis are not readily available; however, three decades of ground-breaking research led by Epistem's founders have culminated in Epistem's preclinical mucositis platform.
To date, over 20 companies have accessed Epistem's preclinical mucositis platform, which incorporates:
Oral Mucositis
Intestinal Mucositis
Dermatology
Epistem draws on its considerable expertise in the epithelial biology field to provide a range of specialist dermatology research services for personal care, cosmetic and pharmaceutical product development.
Epistem also specialises in analysing, using immunohistochemistry, ELISA and gene expression, a range of skin markers (e.g. for differentiation, proliferation, UV protection and anti-ageing) on skin biopsies from 'claims support' human volunteer studies.
Epistem has access to a variety of human skin types and offers expertise and services in the following key areas:
All processes include extensive quality control steps, to ensure a superior data package is delivered to the client.
